Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29719412 | 1.00 | CYP2C19 (0.54) | CYP2C19CYP2C9SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL31145167 | 0.86 | ATM (0.51) | ALDH1A1KDM4ENAMPTCYP17A1 | |
| SCHEMBL7822474 | 0.86 | ATM (0.51) | ALDH1A1KDM4ENAMPTCYP17A1 | |
| SCHEMBL29467524 | 0.84 | NAMPT (0.47) | ALDH1A1KDM4ENAMPTCYP17A1 | |
| SCHEMBL22670446 | 0.84 | NAMPT (0.47) | ALDH1A1KDM4ENAMPTCYP17A1 | |
| SCHEMBL31226336 | 0.82 | NAMPT (0.44) | CYP2C19SMN1; SMN2ALDH1A1KDM4ENAMPT | |
| SCHEMBL4906340 | 0.82 | LMNA (0.44) | CYP2C19CYP2C9SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL31145182 | 0.82 | KDM4E (0.57) | CYP2C19CYP2C9ALDH1A1LMNAKDM4E | |
| SCHEMBL933756 | 0.82 | KDM4E (0.57) | CYP2C19CYP2C9ALDH1A1LMNAKDM4E | |
| SCHEMBL12174559 | 0.82 | NAMPT (0.50) | ALDH1A1KDM4ENAMPTCYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559915-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2025-05-27 | — | — | US | disclosed |
| EP-4013755-B1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | disclosed |
| EP-4013755-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| CN-114585622-A | Piperidinyl-methyl-purinamines as NSD2 inhibitors and anticancer agents | 诺华股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2021028854-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | disclosed |
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | CYP2C19 4555/4885CYP2C9 4511/4885SMN1; SMN2 860/4885 |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | CYP2C19 4555/4885CYP2C9 4511/4885SMN1; SMN2 860/4885 |
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | CYP2C19 813/4885CYP2C9 1908/4885SMN1; SMN2 3953/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | CYP2C19 813/4885CYP2C9 1908/4885SMN1; SMN2 3953/4885 |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NSD2, NSD1, NSD3 | CYP2C19 4555/4885CYP2C9 4511/4885SMN1; SMN2 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.